2. UroToday Home
  3. Actionable Clinical Data
  4. NMIBC with CIS: Evidence, Practice & Emerging Research
  5. Articles
  6. Conferences

AUA 2025

AUA 2025

AUA 2025: A Novel Core Needle Biopsy Instrument Designed for Targeted Biopsy

Details

(UroToday.com) The 2025 AUA annual meeting featured an engineering and urology session and a presentation by Dr. Eric Gwynn discussing a novel core needle biopsy instrument designed for targeted biopsy. Adoption of targeted prostate biopsy is accelerating due to increased detection of clinically significant prostate cancer. However, two significant phenomena with the existing standard of care needles impede maximum sampling of the target: needle deflection and tissue displacement. Standard of care needles capture tissue in a notch located just proximal to the tip of the needle. Several studies have reported deflection of the needle tip as it traverses tissues of varying density, which impedes accurate sampling of target areas and reduces the volume of tissue captured within the notch. The second is the shock wave generated by the needle when fired, which displaces tissues surrounding it. A novel core needle biopsy instrument addresses both phenomena, which is coaxially centered in the outer cannula to prevent deflection:

AUA 2025: Active Surveillance for Clinical Stage T1b Renal Masses in a Large Statewide Collaborative.

Details

(UroToday.com) Dr. Banna Hussain presented important new data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), shedding light on the real-world implementation and outcomes of active surveillance (AS) for clinical stage T1b renal masses (T1bRM, 4.1–7.0 cm). Although nephrectomy remains standard of care, this large-scale, multicenter effort evaluated how non-surgical management is being utilized and associated outcomes that are being observed in patients across the state of Michigan.

AUA 2025: Impact of Prior Holmium Laser Enucleation of the Prostate (HoLEP) on the Accuracy of PI-RADS for Assessing Clinically Significant Prostate Cancer

Details

(UroToday.com) Austin Drysch, from Northwestern University Feinberg School of Medicine, presented an important study evaluating how prior holmium laser enucleation of the prostate (HoLEP) affects the performance of prostate multiparametric MRI (mpMRI) and the associated Prostate Imaging Reporting & Data System (PI-RADS) score for detecting clinically significant prostate cancer (csPCa).

AUA 2025: Robotic-Assisted Partial Nephrectomy in Augmented Reality: Reliability of a Neural Network Training Methodology for Automated Renal Parenchyma Recognition (UROCCR 112)

Details

(UroToday.com) Dr. Alice Pitout and colleagues from Bordeaux and Clermont-Ferrand, France, presented their investigation into the training of a neural network (NN) for the identification of renal parenchyma, for the eventual application into augmented reality (AR) for robotic-assisted partial nephrectomy (RAPN). Currently, their institution has incorporated 3D preoperative models for surgical planning and virtual reality. These have proven to be beneficial, namely in improving patient experience with regard to their understanding of pathology and surgical treatment1. Herein, they are developing an AR software to project and superimpose the 3D models onto the surgical field in real time.

AUA 2025: Panel Discussion – Contemporary Management of Fournier’s Gangrene (Tissue Sparing Debridement, Early Reconstruction and Discharge Planning)

Details

(UroToday.com) A panel of specialists convened to discuss contemporary strategies in the management of Fournier’s gangrene, a life-threatening urological emergency requiring rapid intervention, multidisciplinary care, and long-term reconstruction planning. Moderated by Dr. Steven Hudak, the panel featured Dr. Alex Skokan, Dr. Krishnan Venkatesan, and Dr. Lindsey Hartsell, who shared staged approaches across the phases of Fournier’s disease—from acute infection control to delayed reconstruction.

AUA 2025: Crossfire: Controversies in Urology: Battle of the Guidelines: Examining Key Differences in Evidence-Based Urethral Stricture Management.

Details

(UroToday.com) Tuesday morning’s plenary session featured an excellent crossfire debate on the management of urethral stricture disease. The session compared three sets of global guidelines: the American Urological Association (AUA), European Association of Urology (EAU), and Urological Society of India (USI). Dr. Kenneth Angermeier from the Cleveland Clinic moderated the session, which included panelists Ms. Tamsin Greenwell (EAU), Dr. Pankaj Joshi (USI), and Dr. Hunter Wessells (AUA). Each speaker presented their perspectives on the guidelines, followed by rebuttal arguments, offering insights into the complexities of urethral stricture management.

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

Details
  • New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada
Reno, Nevada (UroToday.com) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without negatively impacting quality of life. The data (Moderated Poster - MP15) were presented at the AUA 2025 Annual Meeting in Las Vegas, Nevada.

AUA 2025: Factors Associated with Elevated Post-Void Residual Urine in Men and Women with Long-Standing Type 1 Diabetes (T1D): The Uro-EDIC Study

Details

(UroToday.com) Dr. Giulia Ippolito from the University of Michigan presented findings from the UroEDIC Study, highlighting factors associated with elevated post-void residual (PVR) urine volumes in men and women living with long-standing type 1 diabetes (T1D).

AUA 2025: Predictive Value of Penile Doppler Ultrasound Impairments

Details

(UroToday.com) Dr. Federico Zorzi presented his research on the potential of arteriogenic insufficiency assessed by penile doppler ultrasound as a predictor for major cardiovascular (CV) events in arteriogenic refractory erectile dysfunction (ED) in response to prostaglandin.

Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits For Patients Suffering from BPH

Details
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT Interventions

Reno, Nevada (UroToday.com) -- Zenflow, Inc. announced the results of long-term data demonstrating that the investigational Zenflow Spring® System offers significant and durable benefits three years after placement. The Zenflow Spring is leading the way in establishing a new category of treatment, First-Line Interventional Therapy or “FIT”, for patients suffering from benign prostatic hyperplasia (BPH) or enlarged prostate. The goal of FIT is to provide clinicians with minimally invasive therapies that offer distinct safety advantages such as ability to reverse treatment if desired, more like a medication. The research was presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas.

AUA 2025: State-of-the-Art Lecture - What is the Role of the Urologist in Trauma Care in 2025?

Details

(UroToday.com) Dr. Sean Elliott, Professor of Urology at the University of Minnesota, delivered a comprehensive and informative presentation addressing the evolving role of urologists in genitourinary trauma management. After stating his financial disclosures (Laborie, study investigator and consultant; Boston Scientific, consultant), he began this plenary by explicitly saying this would not be a review of guidelines, but rather, it is a discussion of where the urologist falls in trauma care. Their role, as he uniquely conceptualized, can be thought of as directly proportional to the proximity of injury to the genitals and inversely proportional to the acuity of the patient. Simply put, urologists lead care in genital and urethral trauma, where precision is crucial and conditions are often stable. As injury sites become more proximal (bladder, ureter, kidney) and patient acuity rises, urologists take on more consultative or collaborative roles—often in conjunction with acute care surgeons. For example, he gave common scenarios of patients who present with gunshot wounds to the genital area, where the urologist would primarily direct management, versus the cases of severe bleeding due to renal trauma, where the trauma surgeon would assume primary responsibility and remove the kidney.

AUA 2025: Rizedisben, a Novel Myelin-Binding Fluorophore for Intraoperative Fluorescent Imaging of Nerve Structures: Phase I Trial in Robotic Radical Prostatectomy

Details

(UroToday.com) The 2025 AUA annual meeting featured a prostate cancer session and a presentation by Dr. Samuel Gold discussing a phase I trial of rizedisben in robotic radical prostatectomy. Rizedisben is a novel myelin-binding fluorophore that fluoresces in the blue light (370-425 nm) spectrum. Iatrogenic nerve injury is a leading cause of morbidity associated with many surgical procedures, thus, fluorescence-guided surgery utilizes enhanced visualization of critical structures to reduce iatrogenic injury or improve critical excisions. The objective of this study, presented at the AUA annual meeting, was to determine the safety of intravenous administration of rizedisben and to determine optimal dose level for sustained fluorescence of nerve structures during intraoperative visualization.

AUA 2025: Erection Function and Bother in Transgender Women Taking Gender Affirming Hormone Therapy and After Pre-Vaginoplasty Bilateral Orchiectomy

Details

(UroToday.com) Dr. Eman Dadashian from the Cedars-Sinai Transgender Surgery and Health Program presented the first study to systematically assess erectile function and related psychological distress in transgender women (TW) undergoing gender-affirming hormone therapy (GAHT), with or without prior bilateral orchiectomy (GABO), prior to vaginoplasty. Dr. Dadashian emphasized that although GAHT and orchiectomy are known to reduce gender dysphoria and eliminate the need for antiandrogens, many transgender women continue to experience erections, which can be a persistent and distressing source of dysphoria.

AUA 2025: State-Of-The-Art Lecture: A Perfect Storm: The Timing, Scope, and Spectrum of Radiation-Induced Complications after Prostate Cancer Treatment

Details

(UroToday.com) Dr. Keith Rourke from the University of Alberta presented on the topic of radiation-induced complications after prostate cancer (PCa) treatment. Dr. Rourke began by highlighting how it has become clear that the long term cancer specific survival for localized PCa is robust. The ProtecT trial demonstrated a 15-year cancer specific survival of over 95% regardless of treatment modality. The 20-year cancer-specific survival is around 80% for patients undergoing radical prostatectomy or brachytherapy and just under 70% for external beam radiation therapy (EBRT).

AUA 2025: Level of Nodal Metastasis in Patients Undergoing Radical Cystectomy and Lymphadenectomy for Muscle-Invasive Urothelial Cancer: Is There Still a Role of Extended Lymphadenectomy in the Post-S1011 Era?

Details

(UroToday.com) Dr. Leilei Xia, Clinical Oncology Fellow at the University of Southern California Norris Comprehensive Cancer Center, presented institutional data examining the impact of the level of nodal metastasis (N⁺) and the incidence of skip metastases in patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) with super-extended lymph node dissection (ELND) in the era following the S1011 trial. While S1011 showed no survival benefit of ELND compared to standard lymph node dissection (SLND), this study aimed to assess whether certain patterns of nodal disease might still inform outcomes or justify extended dissection.

Bladder Cancer Presentations at AUA 2025: Blue Light Cystoscopy Improves Risk Stratification and Informed Decision Making

Details
Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 at the Venetian Convention & Expo Center in Las Vegas, NV, USA.

AUA 2025: Upstaging and Risk Migration with Blue Light Cystoscopy for Non-Muscle-Invasive Bladder Cancer: Results from a Prospective Multicenter Registry

Details

(UroToday.com) The 2025 AUA annual meeting featured a bladder cancer session and a presentation by Dr. Alireza Ghoreifi discussing results from a prospective registry assessing upstaging and risk migration with blue light cystoscopy for non muscle invasive bladder cancer. Blue light cystoscopy is an established procedure for use in the diagnosis and surveillance of patients with non muscle invasive bladder cancer. It is associated with improved detection rates compared to white light cystoscopy, however, limited data are available regarding its role in upstaging and/or upgrading when used alongside white light cystoscopy. The aim of this study presented at the AUA 2025 annual meeting, was to assess the incidence and features of patients undergoing upstaging and/or risk-group migration with the implementation of blue light cystoscopy.

AUA 2025: Oncologic Outcomes in Patients Undergoing Radical Cystectomy for NMIBC Following BCG Therapy Failure

Details

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the PD37: Bladder Cancer: Invasive III Session. Dr. Katharina Oberneder presented PD37-05: Oncologic Outcomes in Patients Undergoing Radical Cystectomy for non–muscle-invasive bladder cancer (NMIBC) Following BCG Therapy Failure.

AUA 2025: Improving Risk Prediction in Radical Cystectomy Patients Using Artificial Intelligence Models

Details

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the PD37: Bladder Cancer: Invasive III Session. Dr Arash Samiei presented PD37-01: Improving Risk Prediction in Radical Cystectomy Patients Using Artificial Intelligence Models.

AUA 2025: Neoadjuvant Therapy with Combined Targeted HER2 and Immunotherapy for T2-T4N0-1M0 Bladder Cancer: A Retrospective Multicenter Study

Details

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the IP24: Bladder Cancer: Invasive II Session. Dr Yongbao Wei presented a Retrospective Multicenter Study evaluating Neoadjuvant Therapy with Combined Targeted HER2 and Immunotherapy for T2-T4N0-1M0 Bladder Cancer.